Prostate cancer incidence and mortality in a given population are influenced by frequency of PSA testing; therefore, in the context of prostate cancer, healthy user bias may cause falsely elevated overall prostate cancer risk but lowered disease-specific mortality among users compared to non-users due to more active participation in PSA testing. This evidence concerns the gene KLK3 and prostate cancer.